Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept (Tai'ai) in Generalized Myasthenia Gravis
CTR20230297Phase 3Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Feb 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in myasthenia gravis (MG), sponsored by Rongchang Pharmaceuticals. Started Feb 2023; status: completed.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20230297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230297.